Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium

Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion

(2018) Ramona Schulz-Heddergott et al.   CANCER CELL

Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner

(2017) Evguenia M Alexandrova et al.   Cell Death & Disease

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)

(2015) S. Ramalingam et al.   ANNALS OF ONCOLOGY

Survival of women with cancers of breast and genital organs in Europe 1999–2007: Results of the EUROCARE-5 study

(2015) Milena Sant et al.   EUROPEAN JOURNAL OF CANCER

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment

(2015) E. M. Alexandrova et al.   NATURE

First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors

(2014) G. I. Shapiro et al.   CLINICAL CANCER RESEARCH

Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer

(2014) Martin R. Stockler et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

(2014) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis

(2013) W Hanel et al.   CELL DEATH AND DIFFERENTIATION

First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors

(2013) C. Sessa et al.   CLINICAL CANCER RESEARCH

A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors

(2013) Dan Zhou et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models

(2012) David A. Proia et al.   INVESTIGATIONAL NEW DRUGS

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

(2011) D Li et al.   CELL DEATH AND DIFFERENTIATION

A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas

(2011) A. Rajan et al.   CLINICAL CANCER RESEARCH

Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)

(2011) Gordon John Sampson Rustin et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells

(2011) D. Li et al.   MOLECULAR CANCER RESEARCH

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

(2010) Ahmed Ashour Ahmed et al.   JOURNAL OF PATHOLOGY

Weekly paclitaxel in the treatment of recurrent ovarian cancer

(2010) Richard D. Baird et al.   Nature Reviews Clinical Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER